Protect – Type 1 Diabetes Study
Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab, in Children and Adolescents, Newly Diagnosed Type 1 Diabetes

Type of Study:
Newly diagnosed adolescents 8-17 years old with Type 1 diabetes

Study Length:
18 months

Target Age/Sex:
8 to 17 years old, Male and Female

Participants will receive at no cost: study product, study materials and study-specific procedures


Staus: On Hold


The Protect study will determine whether teplizumab slows the loss of β cells and preserves β cell function in children and adolescent 8-17 years old who have been diagnosed with T1D in the previous 6 weeks.

This Study is On Hold.